Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Royal Bank of Canada

Royal Bank of Canada trimmed its holdings in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 50.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 145,713 shares of the company’s stock after selling 145,556 shares during the period. Royal Bank of Canada owned 0.11% of Henry Schein worth $9,583,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in HSIC. Dark Forest Capital Management LP acquired a new stake in Henry Schein in the 2nd quarter valued at about $34,000. Ronald Blue Trust Inc. acquired a new stake in Henry Schein in the 2nd quarter valued at about $37,000. Ellevest Inc. lifted its holdings in Henry Schein by 231.8% in the 3rd quarter. Ellevest Inc. now owns 564 shares of the company’s stock valued at $37,000 after purchasing an additional 394 shares in the last quarter. Guardian Wealth Advisors LLC purchased a new position in Henry Schein in the 3rd quarter valued at about $51,000. Finally, Kistler Tiffany Companies LLC lifted its holdings in Henry Schein by 31.6% in the 3rd quarter. Kistler Tiffany Companies LLC now owns 1,053 shares of the company’s stock valued at $69,000 after purchasing an additional 253 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Henry Schein Trading Down 0.7 %

NASDAQ:HSIC opened at $77.25 on Friday. The stock has a market cap of $10.14 billion, a PE ratio of 19.86, a price-to-earnings-growth ratio of 1.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.79 and a quick ratio of 0.91. Henry Schein, Inc. has a fifty-two week low of $64.75 and a fifty-two week high of $92.68. The stock’s 50-day moving average is $82.36 and its two-hundred day moving average is $77.14.

Henry Schein (NASDAQ:HSIC – Get Rating) last released its quarterly earnings data on Thursday, February 16th. The company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.14. The business had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. Henry Schein’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 earnings per share. As a group, equities research analysts forecast that Henry Schein, Inc. will post 5.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HSIC shares. StockNews.com upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Thursday, January 19th. Piper Sandler upped their target price on shares of Henry Schein from $85.00 to $97.00 and gave the company an “overweight” rating in a report on Monday, February 6th. UBS Group upped their target price on shares of Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a report on Tuesday. Morgan Stanley cut their price objective on shares of Henry Schein from $70.00 to $69.00 and set an “underweight” rating on the stock in a report on Tuesday, February 21st. Finally, Barrington Research cut their price target on shares of Henry Schein from $99.00 to $92.00 and set an “outperform” rating on the stock in a report on Friday, February 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $85.89.

Insider Buying and Selling

In other Henry Schein news, SVP Lorelei Mcglynn sold 15,341 shares of the firm’s stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $80.70, for a total value of $1,238,018.70. Following the completion of the transaction, the senior vice president now directly owns 73,753 shares in the company, valued at $5,951,867.10. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Henry Schein news, CEO Stanley M. Bergman sold 54,216 shares of the stock in a transaction dated Monday, December 12th. The stock was sold at an average price of $81.16, for a total value of $4,400,170.56. Following the completion of the transaction, the chief executive officer now directly owns 488,126 shares in the company, valued at $39,616,306.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Lorelei Mcglynn sold 15,341 shares of the stock in a transaction dated Tuesday, December 20th. The shares were sold at an average price of $80.70, for a total value of $1,238,018.70. Following the completion of the transaction, the senior vice president now owns 73,753 shares of the company’s stock, valued at $5,951,867.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 82,802 shares of company stock worth $6,694,575. 1.00% of the stock is owned by corporate insiders.

Henry Schein Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins.